Edition:
United States

Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

12.64USD
16 Nov 2018
Change (% chg)

$-0.20 (-1.56%)
Prev Close
$12.84
Open
$12.65
Day's High
$12.89
Day's Low
$12.02
Volume
537,544
Avg. Vol
237,970
52-wk High
$27.00
52-wk Low
$8.36

Latest Key Developments (Source: Significant Developments)

Sandoz Amends ANDA To Not Seek Approval For Generic Version Of Omidria
Thursday, 26 Jul 2018 07:30am EDT 

July 26 (Reuters) - Omeros Corp ::SANDOZ AMENDS ANDA TO NOT SEEK APPROVAL FOR GENERIC VERSION OF OMIDRIA UNTIL PATENTS FOR OMEROS’ DRUG EXPIRE.OMEROS CORP - WITH VOLUNTARY DISMISSAL OF INFRINGEMENT SUIT AGAINST SANDOZ, OMEROS WRAPS UP ALL PENDING ANDA LITIGATION.  Full Article

Omeros Says Entered Into Settlement Agreement And Consent Judgment With Lupin Ltd and unit Lupin Pharmaceuticals - SEC Filing
Thursday, 24 May 2018 08:27am EDT 

May 24 (Reuters) - Lupin Ltd ::OMEROS SAYS ENTERED INTO SETTLEMENT AGREEMENT AND CONSENT JUDGMENT WITH LUPIN LTD, SUBSIDIARY LUPIN PHARMACEUTICALS - SEC FILING.OMEROS - AGREEMENT RESOLVES CO'S PATENT LITIGATION AGAINST LUPIN.OMEROS CORP - LUPIN ACKNOWLEDGED & CONFIRMED VALIDITY OF EACH OF PATENTS LISTED IN ORANGE BOOK FOR OMIDRIA.OMEROS CORP - PARTIES EXECUTED CONSENT JUDGMENT THAT WAS FILED WITH COURT FOR DISTRICT ON MAY 23, 2018.OMEROS - LUPIN GRANTED LICENSE TO MAKE, SELL GENERIC VERSION OF OMIDRIA BETWEEN PERMITTED LAUNCH DATE & LATEST EXPIRATION OF CO'S U.S. PATENTS.OMEROS CORP - LUPIN IS GRANTED NON-EXCLUSIVE, NON-SUBLICENSABLE WAIVER OF CO'S PEDIATRIC EXCLUSIVITY FOR OMIDRIA UNTIL AT LEAST APRIL 23, 2034.  Full Article

Omeros Q4 Loss Per Share $0.34
Thursday, 1 Mar 2018 04:02pm EST 

March 1 (Reuters) - Omeros Corp ::REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.34.Q4 REVENUE $13.8 MILLION.  Full Article

European Medicines Agency Issues Orphan Drug Designation Positive Opinion for Omeros' OMS721
Monday, 22 Jan 2018 07:00am EST 

Jan 22 (Reuters) - Omeros Corp ::EUROPEAN MEDICINES AGENCY ISSUES ORPHAN DRUG DESIGNATION POSITIVE OPINION FOR OMEROS’ OMS721 IN THE TREATMENT OF IGA NEPHROPATHY.OMEROS CORP - EMA ALSO REVIEWING PRIORITY MEDICINES APPLICATION FOR DRUG IN IGAN.OMEROS CORP - POSITIVE OPINION ISSUED BY COMP IS EXPECTED TO BE ADOPTED BY EUROPEAN COMMISSION AT ITS FEBRUARY MEETING.  Full Article

Omeros Reaches Agreement With FDA On OMS721 Phase 3 Trial Protocol For IgA Nephropathy
Wednesday, 3 Jan 2018 07:00am EST 

Jan 3 (Reuters) - Omeros Corp ::OMEROS CORPORATION REACHES AGREEMENT WITH FDA ON OMS721 PHASE 3 TRIAL PROTOCOL FOR IGA NEPHROPATHY.OMEROS CORPORATION REACHES AGREEMENT WITH FDA ON OMS721 PHASE 3 TRIAL PROTOCOL FOR IGA NEPHROPATHY.OMEROS CORP - ‍INITIATES OMS721 PHASE 3 PROGRAM IN HCT-TMA​.OMEROS CORP - ‍ PATIENT ENROLLMENT FOR ITS PHASE 3 CLINICAL TRIAL EVALUATING OMS721 IN PATIENTS WITH IGA NEPHROPATHY IS EXPECTED TO BEGIN EARLY IN FEB.  Full Article

Omeros Corporation Announces Fda Approval Of Omidria For Use In Pediatric Patients
Tuesday, 12 Dec 2017 07:00am EST 

Dec 12 (Reuters) - Omeros Corp ::OMEROS CORPORATION ANNOUNCES FDA APPROVAL OF OMIDRIA® FOR USE IN PEDIATRIC PATIENTS.FDA APPROVED SNDA FOR OMIDRIA UNDER PRIORITY REVIEW.  Full Article

Omeros Corp reports Q3 loss per share $0.16
Thursday, 9 Nov 2017 04:02pm EST 

Nov 9 (Reuters) - Omeros Corp :Omeros Corporation reports third quarter 2017 financial results.Q3 loss per share $0.16.Q3 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S.Q3 revenue $21.7 million versus i/b/e/s view $17.9 million.Omeros Corp - ‍as of sept 30, 2017, co had $86.8 million of cash & cash equivalents available for operations & $5.8 million in restricted cash​.  Full Article

OMEROS REPORTS ADDITIONAL POSITIVE DATA FOR OMS721
Thursday, 26 Oct 2017 11:30am EDT 

Oct 26 (Reuters) - Omeros Corp ::OMEROS REPORTS ADDITIONAL AND CONSISTENTLY POSITIVE DATA FOR OMS721 IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY.‍OMS721 HAS BEEN WELL TOLERATED AND NO SAFETY CONCERNS HAVE BEEN IDENTIFIED​.3 OF 4 PATIENTS FOR WHOM OMS721 TREATMENT WAS DISCONTINUED EARLY EXPERIENCED DETERIORATION OF THEIR CONDITIONS AND SUBSEQUENTLY DIED​.‍PREPARING TO INITIATE OMS721 PHASE 3 CLINICAL TRIAL, PURSUING FDA'S BREAKTHROUGH THERAPY DESIGNATION, EUROPEAN MEDICINES AGENCY'S PRIME STATUS​.  Full Article

Omeros Corp amends term loan agreement
Tuesday, 17 Oct 2017 09:02am EDT 

Oct 17 (Reuters) - Omeros Corp :On Oct 11, co entered amendment no. 1 to loan agreement, which amended term loan agreement, dated October 26, 2016​.Pursuant to amendment, co to access second, third tranches of debt financing under loan agreement for up to $25 million and $20 million.  Full Article

OMEROS ANNOUNCES SETTLEMENT OF INFRINGEMENT SUIT AGAINST ANDA FILER PAR
Thursday, 5 Oct 2017 11:00am EDT 

Oct 5 (Reuters) - Omeros Corp ::OMEROS ANNOUNCES SETTLEMENT OF INFRINGEMENT SUIT AGAINST ANDA FILER PAR.ENTERED INTO A SETTLEMENT AGREEMENT WITH PAR PHARMACEUTICAL, INC. AND ITS SUBSIDIARY RESOLVING OMEROS' PATENT LITIGATION AGAINST PAR​.UNDER SETTLEMENT, PAR TO PAY TO CO ROYALTY OF 15% OF PAR'S NET SALES OF ANY GENERIC VERSION OF OMIDRIA UNTIL LATEST EXPIRATION OF PATENTS.‍LAST-TO-EXPIRE OF OMEROS' ORANGE BOOK LISTED PATENTS FOR OMIDRIA EXPIRES ON OCTOBER 23, 2033​.UNLESS SUBSEQUENTLY AUTHORIZED IN SETTLEMENT AGREEMENT, PAR WILL BE PROHIBITED FROM LAUNCHING GENERIC VERSION OF OMIDRIA UNTIL APRIL 1, 2032.  Full Article

BRIEF-Omeros Says Entered Into Settlement Agreement And Consent Judgment With Lupin Ltd and unit Lupin Pharmaceuticals - SEC Filing

* OMEROS SAYS ENTERED INTO SETTLEMENT AGREEMENT AND CONSENT JUDGMENT WITH LUPIN LTD, SUBSIDIARY LUPIN PHARMACEUTICALS - SEC FILING